Q3 EPS Estimate for Corcept Therapeutics Lifted by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of Corcept Therapeutics in a research note issued on Thursday, July 30th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.78 per share for the quarter, up from their previous forecast of $0.34. HC Wainwright has a “Buy” rating and a $165.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.13 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $1.31 EPS, FY2026 earnings at $2.15 EPS, Q1 2027 earnings at $0.74 EPS, Q2 2027 earnings at $1.03 EPS, Q3 2027 earnings at $1.32 EPS, Q4 2027 earnings at $1.40 EPS and FY2027 earnings at $3.95 EPS.

Several other brokerages have also recently issued reports on CORT. Piper Sandler restated an “overweight” rating and set a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Canaccord Genuity Group lifted their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. UBS Group set a $135.00 price target on Corcept Therapeutics in a report on Thursday, May 28th. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research report on Monday, July 27th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $119.17.

Corcept Therapeutics Stock Performance

NASDAQ:CORT opened at $112.80 on Monday. The company has a market capitalization of $12.19 billion, a price-to-earnings ratio of 268.58 and a beta of 0.45. Corcept Therapeutics has a one year low of $28.66 and a one year high of $122.21. The stock has a 50-day simple moving average of $85.82 and a 200 day simple moving average of $57.45.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The business had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. During the same quarter in the prior year, the business posted $0.29 EPS. The company’s revenue for the quarter was up 31.7% on a year-over-year basis.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider William Guyer sold 20,000 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $93.13, for a total transaction of $1,862,600.00. Following the sale, the insider owned 3,985 shares in the company, valued at $371,123.05. This represents a 83.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James N. Wilson sold 10,000 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $83.20, for a total transaction of $832,000.00. Following the sale, the director owned 1,094,543 shares in the company, valued at approximately $91,065,977.60. This trade represents a 0.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 360,000 shares of company stock worth $30,228,250. 20.70% of the stock is owned by company insiders.

Institutional Trading of Corcept Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter worth approximately $25,000. Larson Financial Group LLC grew its stake in Corcept Therapeutics by 2,326.3% during the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock worth $38,000 after buying an additional 442 shares during the last quarter. Gould Capital LLC grew its stake in Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after buying an additional 200 shares during the last quarter. Torren Management LLC acquired a new stake in Corcept Therapeutics in the fourth quarter worth $25,000. Finally, CIBC Private Wealth Group LLC increased its position in Corcept Therapeutics by 128.5% in the third quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock worth $64,000 after buying an additional 433 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.